Previous 10 | Next 10 |
Sintx Technologies (NASDAQ: SINT ) -11% . More news on: Sintx Technologies, Inc., Sierra Metals Inc., Hertz Global Holdings, Inc., Stocks on the move, , Read more ...
There are many levels to the coronavirus pandemic and a massive effort is underway to find a vaccine and treatments. Genetic Engineering News summarised 161+ candidates. The US clinical trials website indicates 1,915 trials underway using the keyword COVID-19 (June 3, 2020). The common c...
The need for medicines that help Covid-19 patients before the disease leaves the viral response phase and enters the host inflammatory phase has never been greater. While there are some positive signals in the prevention area, the most frequent estimates I am reading place a realistic timeli...
NEW YORK, June 01, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that treatment with its lead mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with...
Mesoblast Ltd (MESO) Q4 2020 Earnings Conference Call May 27, 2020 06:00 PM ET Corporate Participants Silviu Itescu - CEO Josh Muntner - CFO Fred Grossman - CMO Conference Call Participants Louise Chen - Cantor Jeffrey Cohen - Ladenburg Thalmann Jason Folger - Dawson Ja...
The following slide deck was published by Mesoblast Limited in conjunction with their 2020 Q3 earnings Read more ...
Image source: The Motley Fool. Mesoblast Limited (NASDAQ: MESO) Q3 2020 Earnings Call May 27, 2020 , 6:00 p.m. ET Operator Continue reading
Mesoblast (NASDAQ: MESO ): Q3 GAAP EPS of -$0.0284 beats by $0.13 . More news on: Mesoblast Limited, Earnings news and commentary, Healthcare stocks news, Read more ...
NEW YORK, May 27, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial, corporate and operational highlights for the nine months ended March 31, 2020. Cash on hand at March 31, 2...
NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the financial results for the period ended March 31, 2020. The webcast will begin at 6pm EDT Wednesday, Ma...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...